European Journal of Endocrinology最新文献

{"title":"Hysterectomy, oophorectomy, and bone health: a systematic review and meta-analysis.","authors":"Md Shariful Islam, Karen M Tuesley, Louise F Wilson, Junru Zhou, Aishi Aratrika, Susan J Jordan","doi":"10.1093/ejendo/lvaf177","DOIUrl":"10.1093/ejendo/lvaf177","url":null,"abstract":"<p><strong>Objective: </strong>To review the association between hysterectomy, with and without oophorectomy, and fracture, osteoporosis, and bone mineral density (BMD) change.</p><p><strong>Methods: </strong>We undertook a systematic review and meta-analysis, searching PubMed, Embase, Cochrane Central, and CINAHL from inception to November 2024. Eligible studies included women aged ≥18 years and assessed the relationship between having a hysterectomy and/or oophorectomy and fracture, osteoporosis, or BMD.</p><p><strong>Results: </strong>Of 15 305 articles screened, 29 met the inclusion criteria, with 19 included in the meta-analyses. Bilateral oophorectomy compared to no oophorectomy was associated with a higher risk of fracture (pooled relative risk [RR] 1.17, 95% CI 1.03-1.33, 10 studies) and osteoporosis, although the latter was not statistically significant (RR 1.46, 95% CI 0.94-2.27, 4 studies). Hysterectomy with bilateral oophorectomy was not associated with a higher fracture risk compared to hysterectomy without oophorectomy (RR 0.99; 95% CI 0.83-1.18, 4 studies). However, hysterectomy without oophorectomy compared to no surgery was associated with a higher osteoporosis risk (RR 1.45; 95% CI 1.37-1.53, 2 studies). Findings showed moderate to high heterogeneity, and most studies did not account for variables such as age at surgery, menopausal hormone therapy use, and indications for surgery.</p><p><strong>Conclusions: </strong>Our review supports evidence showing that bilateral oophorectomy is negatively associated with bone health and suggests that hysterectomy alone may also increase osteoporosis risk, although more data are required. To support personalised clinical decision-making, further large-scale longitudinal studies with longer follow-up and detailed assessment of surgery extent, timing, and medication use are essential.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"S15-S25"},"PeriodicalIF":5.2,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT).","authors":"Lynnette K Nieman, Marco Boscaro, Carla Scaroni, Timo Deutschbein, Emese Mezôsi, Natacha Driessens, Carmen E Georgescu, Marcin Motyka, Alicja Hubalewska-Dydejczyk, Barbara Jarzab, Dominique Maiter, Martin Reincke, Paola Loli, Benedetta Zampetti, Aysegul Atmaca, Corin Badiu, Albert Beckers, Marek Bolanowski, Francesco Cavagnini, Nicole Unger, Roberta Giordano, Felicia Alexandra Hanzu, Massimo Terzolo, Myriam Bou Nader, Ninet Sinaii, Judit Tőke, Miklós Tóth","doi":"10.1093/ejendo/lvaf181","DOIUrl":"10.1093/ejendo/lvaf181","url":null,"abstract":"<p><strong>Objective: </strong>We evaluated the safety and efficacy of metyrapone treatment for Cushing's syndrome (CS).</p><p><strong>Design: </strong>International, prospective, single-arm, open-label study.</p><p><strong>Methods: </strong>Fifty adults with endogenous CS (either unsuitable for or uncontrolled after surgery) and 3 urinary free cortisol (UFC) concentrations each ≥1.5-fold the upper limit of normal (ULN) were enrolled. After 12 weeks of metyrapone titration, participants with mean 24 h UFC (mUFC) ≤ 2-fold ULN could enter a 24-week extension phase. Safety was assessed, and doses adjusted at weeks 1-5, 8, 12, and 24. Pre-defined endpoints included normalization of mUFC at weeks 12 (primary), 24, and 36, and proportion of \"responders\" (normalization or ≥50% decrease of baseline mUFC), time to eucortisolemia, salivary cortisol day-curve, and quality of life (QoL).</p><p><strong>Results: </strong>Of the 49 evaluable participants, 47 completed the 12-week visit; 40 were evaluated at week 24 and 35 at week 36. The primary endpoint was met in 46.9% of participants (95% CI 32.5%-61.7%), with efficacy maintained at week 24 (52.5%; 95% CI 37.5%-67.1%) and week 36 (48.6%; 95% CI 33.0%-64.4%). The responder rates were 80.9%, 77.5%, and 71.4% at weeks 12, 24, and 36, respectively. Forty-seven participants (94%) developed mild-to-moderate adverse events (AEs), mostly during the first 12 weeks and most commonly nausea (38%), fatigue (26%), and headache (22%); 8 experienced severe AEs. Six participants developed reversible adrenal insufficiency during titration. Clinical features and QoL improved.</p><p><strong>Conclusion: </strong>Metyrapone is a safe and effective treatment for endogenous CS.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"391-402"},"PeriodicalIF":5.2,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolving landscape of thyroid eye disease: present and future.","authors":"David Toro-Tobon, Marius N Stan","doi":"10.1093/ejendo/lvaf156","DOIUrl":"10.1093/ejendo/lvaf156","url":null,"abstract":"<p><p>Thyroid eye disease (TED) is a complex ocular autoimmune disorder primarily associated with Graves' disease. It leads to significant morbidity due to orbital inflammation, fibrosis, and tissue expansion. While corticosteroids have been the traditional mainstay of therapy, recent advancements in understanding TED pathophysiology have driven the development of targeted treatments. Notably, inhibition of the insulin-like growth factor-1 receptor with teprotumumab has revolutionized TED management, demonstrating efficacy in reducing proptosis and disease severity. Additional emerging therapies, including neonatal Fc receptor inhibitors, thyroid-stimulating hormone receptor blockers, and interleukin-6 receptor antagonists, offer promising alternatives for patients with active and refractory disease. Despite these advancements, challenges remain in disease classification and outcome assessment. As the landscape of TED management continues to evolve, this review provides a comprehensive overview of current and emerging therapies for TED, critically examines gaps in disease evaluation, and highlights the evolving paradigm of patient-centered care. Future efforts should focus on optimizing therapeutic algorithms, refining risk stratification models, guiding personalized treatment, and promoting a multidisciplinary approach, which remain essential in improving outcomes and quality of life for affected individuals.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"R15-R24"},"PeriodicalIF":5.2,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of genetics in the age-related testosterone decline in men: a UK Biobank study.","authors":"Lynn Ogoniak, Sarah Sandmann, Julian Varghese, Michael J Ziller, Nina Neuhaus, Alexander Siegfried Busch","doi":"10.1093/ejendo/lvaf143","DOIUrl":"10.1093/ejendo/lvaf143","url":null,"abstract":"<p><strong>Objective: </strong>Age-related decline in circulating testosterone (T) levels in men varies significantly and is often linked to comorbidities such as Type 2 diabetes and cardiovascular disease (CVD). While the genetic basis of T levels is well studied, the role of genetics in age-related T decline remains unclear. This study aims to investigate the genetic contribution to age-related T decline in men and its association with comorbidities.</p><p><strong>Design: </strong>A longitudinal, population-based study in 6354 men including consecutive T, bioavailable testosterone (BAT), and sex hormone-binding globulin (SHBG) measurements.</p><p><strong>Methods: </strong>We assessed the association of longitudinal serum biomarker changes with changes in disease prevalences and a polygenic score (PGS) for BAT developed in 183 909 UK Biobank participants.</p><p><strong>Results: </strong>In the follow-up cohort (mean age: 58.2 years; mean follow-up: 4.3 years), baseline levels of BAT, T, and SHBG were each negatively associated with their respective relative changes at follow-up (all P < .001). A PGS for BAT, strongly associated with baseline levels (P = 2.2 × 10-16, R²=0.16), was not associated with BAT decline over time. Genome-wide analysis of BAT change identified no significant genetic loci. Instead, the BAT decline was associated with prevalence of several comorbidities including cancers and CVD (P = .007 and .012, respectively).</p><p><strong>Conclusions: </strong>Non-genetic factors are strongly associated with age-related BAT decline, whereas genetic predisposition may have a limited role. However, this does not rule out a potential genetic contribution. Our findings offer insight into the relationship between comorbidities and hormonal changes, supporting further research into their roles in T decline and related health risks in aging men.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"197-203"},"PeriodicalIF":5.2,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine manifestations in a paediatric cohort of 181 patients with neurofibromatosis type 1.","authors":"Catarina Regala, Daniela Cavaco, Joana Maciel, Ana Figueiredo, Inês Damásio, Sara Pinheiro, João Passos, Sara Donato","doi":"10.1093/ejendo/lvaf147","DOIUrl":"10.1093/ejendo/lvaf147","url":null,"abstract":"<p><strong>Objective: </strong>Endocrine disorders in patients with neurofibromatosis type 1 (NF1) are well established, but have been mainly described in single case reports or small series. Our aim is to characterize the endocrine manifestations of a NF1 paediatric population in a single centre.</p><p><strong>Design: </strong>Retrospective analysis of paediatric NF1 patients followed in the Endocrinology Department of Portuguese Institute of Oncology of Lisbon between 1997 and 2023.</p><p><strong>Methods: </strong>Patients were identified using our centre's NF1 database.</p><p><strong>Results: </strong>A total of 181 patients (100 males) were included in the study. The overall prevalence of endocrinopathies was 23.2%, with a significantly higher rate in patients with optic pathway glioma (OPG) compared with those without (32.9% vs. 16.7%, P = .011). Puberty disorders were the most common endocrine dysfunction (12.2%), more frequent in children with OPG (19.2% vs. 7.4%, P = .011). Growth hormone deficiency (GHD) was the second most prevalent (9.9%), also more common among children with OPG (17.8% vs. 4.9%, P = .004). Less frequent abnormalities included central hypogonadism (n = 2, 1.1%), observed only in patients without OPG, and central hypothyroidism with ACTH deficiency (0.6%) in a child with panhypopituitarism. Primary hypothyroidism with thyroid nodules was identified in 1 patient (0.6%), and gynaecomastia was noted in 4 children (2.2%).</p><p><strong>Conclusions: </strong>Puberty disorders and GHD were the most frequent disorders in our cohort. This study highlights the high prevalence of different endocrine manifestations associated with NF1, even without OPG, reinforcing the need to develop referral criteria and follow-up protocols.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"216-222"},"PeriodicalIF":5.2,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of pituitary radiotherapy and their predictive factors in childhood and adolescent-onset Cushing disease.","authors":"Raghavendra Pandit, Chethan Yami Channaiah, Anurag Ranjan Lila, Manjiri Karlekar, Vijaya Sarathi, Saba Samad Memon, Rohit Barnabas, Tejpal Gupta, Nalini Shah, Tushar Bandgar","doi":"10.1093/ejendo/lvaf149","DOIUrl":"10.1093/ejendo/lvaf149","url":null,"abstract":"<p><strong>Objective: </strong>Radiotherapy (RT) is an established second-line treatment in adult Cushing disease (CD). Data on pituitary RT in childhood and adolescent-onset CD is scarce. This study aims to demonstrate the effectiveness and long-term safety of fractionated conformal-RT (CRT) in childhood and adolescent-onset CD patients.</p><p><strong>Methods: </strong>This single-center retrospective study included 34 out of 108 CD patients (<20 years at presentation) who underwent first-line, second-line (post-first transsphenoidal-surgery), or third-line (post-second transsphenoidal-surgery) CRT between 1994 and 2024, with a minimum 1-year follow-up post-CRT.</p><p><strong>Results: </strong>Data from 34 patients (21 males, 7 prepubertal, and 24 microadenomas) with post-CRT median follow-up of 74.5 (34.5-127.3) months were analyzed. Post-CRT, 25/34 (73.5%) patients (overall cohort) achieved remission at 16.5 (8.75-39.25) months, with remission rates of 60%, 93.8%, and 53.8% in first, second, and third-line CRT, respectively. Younger age at CD diagnosis was an independent predictor of remission (HR: 0.805, P = .02). Relapse occurred in 6/25 (24%) at 19.0 (18.3-30.3) months. Ketoconazole use predicted relapse post-CRT (P = .006). Growth hormone deficiency occurred in 17/20 (85%), and 29/34 (41.4%) patients had low insulin-like growth factor-1 levels. New-onset hypogonadotropic hypogonadism (HH) and central hypothyroidism (CHT) occurred in 3/24 (12.5%) and 4/24 (16.7%) patients, respectively. Older age at CD diagnosis (17.5 vs. 13.0 years; P = .02) and at CRT administration (23 vs. 14 years; P = .04) predicted new-onset HH and/or CHT post-CRT.</p><p><strong>Conclusion: </strong>Our study illustrates the favorable remission rates post-CRT in childhood and adolescent CD, with lower rates of new-onset HH/CHT. Ongoing monitoring is required, as relapse can occur in one-fourth of cases.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"223-231"},"PeriodicalIF":5.2,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes.","authors":"Maria Luisa Brandi, Tamara Vokes, Natasha M Appelman-Dijkstra, Olulade Ayodele, Brigitte Decallonne, Renate de Jongh, Manuel Díaz-Curiel, William Fraser, Richard D Finkelman, Ansgar Heck, Steven W Ing, Peter Kamenický, Aliya A Khan, Christopher S Kovacs, Bruno Lapauw, Graham Leese, Giovanna Mantovani, Guillermo Martínez Díaz-Guerra, Laura Masi, Miguel Melo, Andrea Palermo, Narendra L Reddy, Lars Rejnmark, Elena Tokareva, Marie-Christine Vantyghem, Suwei Wang, Mark Warren, Brian Yan","doi":"10.1093/ejendo/lvaf148","DOIUrl":"10.1093/ejendo/lvaf148","url":null,"abstract":"<p><strong>Objective: </strong>To assess the impact of recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] compared with placebo, in combination with conventional therapy with vitamin D and/or calcium supplements, on health-related quality of life (HRQoL) in patients with symptomatic chronic hypoparathyroidism (cHypoPT).</p><p><strong>Design: </strong>Randomized, double-blind, placebo-controlled, phase 3b-4 study (ClinicalTrials.gov ID: NCT03324880).</p><p><strong>Methods: </strong>Eligible patients with symptomatic cHypoPT were randomized to receive subcutaneous rhPTH(1-84) 25-100 µg/day or placebo. The primary endpoint was the change from baseline to week 26 in Hypoparathyroidism Symptom Diary (HypoPT-SD) symptom subscale score. Key secondary endpoints were changes from baseline to week 26 in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue and in 36-item Short Form Health Survey physical component summary (SF-36v2 PCS).</p><p><strong>Results: </strong>In total, 93 patients were randomized to receive treatment: 45 received rhPTH(1-84) and 48 received placebo. Change from baseline to week 26 in HypoPT-SD symptom subscale score was significantly greater (improved) in the rhPTH(1-84) group than in the placebo group (difference in least-squares mean changes, -0.53; 95% confidence interval, -0.90 to -0.15, P = .003). Key secondary endpoints, changes between baseline and week 26 in the FACIT-Fatigue and SF-36v2 PCS scores were also significantly greater (improved) in the rhPTH(1-84) group than in the placebo group. The safety profile of rhPTH(1-84) was consistent with previous findings, and no new safety signals were identified.</p><p><strong>Conclusions: </strong>rhPTH(1-84) alongside conventional therapy improved symptom burden (as measured by the HypoPT-SD) and HRQoL to a greater extent than conventional therapy alone in patients with symptomatic cHypoPT.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"310-319"},"PeriodicalIF":5.2,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: Ketone supplementation acutely lowers androgen and glucose levels in women with polycystic ovary syndrome: a randomized clinical trial.","authors":"Nikolaj Rittig, Mai C Arlien-Søborg, Mads V Svart, Henrik H Thomsen, Kirstine Kirkegaard, Vinnie H Greve, Mette M Nielsen, Kirstine Stochholm, Marie J Ornstrup, Claus H Gravholt","doi":"10.1093/ejendo/lvaf164","DOIUrl":"10.1093/ejendo/lvaf164","url":null,"abstract":"","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"L12-L13"},"PeriodicalIF":5.2,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phosphate concentration is exceptionally high in seminal fluid and is linked with semen quality but not influenced by vitamin D and calcium supplementation.","authors":"Frederikke Bay Toft, Sam Kafai Yahyavi, Mads Joon Jorsal, Ida Marie Boisen, Zhihui Cui, Niels Jørgensen, Anders Juul, Rune Holt, Martin Blomberg Jensen","doi":"10.1093/ejendo/lvaf146","DOIUrl":"10.1093/ejendo/lvaf146","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to determine the link between seminal fluid (SF) concentrations of phosphate with semen quality parameters, corresponding serum phosphate concentration, and possible influence of high-dose cholecalciferol and calcium supplementation.</p><p><strong>Materials and methods: </strong>In a single-center, double-blinded, randomized clinical trial (NCT01304927), 307 infertile men were assigned to receive a single dose of vitamin D (cholecalciferol) 300 000 IU initially followed by 1400 IU and 500 mg of calcium daily for 150 days or placebo. Change in SF phosphate was a predefined secondary endpoint while effect on semen parameters was the primary endpoint.</p><p><strong>Results: </strong>At baseline, SF phosphate concentration was 25-fold higher but not associated with serum phosphate concentration (median 24.0 mmol/L [IQR 17, 30] vs 0.93 mmol/L [IQR 0.83, 1.05]). Men with the highest concentration of SF phosphate (≥29 mmol/L) had fewer motile spermatozoa (AB%: median 27% [IQR 14, 39] vs 37% [IQR 17, 56]; P = .007) and morphologically normal spermatozoa (1.9% [IQR 0.8, 3.8] vs 2.5% [IQR 1.4, 6.5]; P = .014) than men having SF phosphate < 19 mmol/L. Seminal fluid concentrations of phosphate remained stable and were unaffected by vitamin D and calcium supplementation (SF phosphate in placebo median 21.4 [IQR 15.9, 28.4] vs treatment 21.1 [IQR 14.5, 29.8]).</p><p><strong>Conclusion: </strong>Seminal fluid phosphate concentration may be of importance for reproductive function as infertile men with the lowest SF phosphate concentration had higher percentage of motile and morphologically normal spermatozoa. Serum phosphate concentration was not associated with seminal phosphate levels, and cholecalciferol and calcium supplementation did not influence SF phosphate.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"240-246"},"PeriodicalIF":5.2,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex steroid hormones and subclinical atherosclerosis progression.","authors":"Rongrong Chen, Lin Sheng, Xiaohan Zhang, Lanyun Xie","doi":"10.1093/ejendo/lvaf134","DOIUrl":"https://doi.org/10.1093/ejendo/lvaf134","url":null,"abstract":"","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":"193 2","pages":"L5-L6"},"PeriodicalIF":5.2,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}